The Progress Of Research On Vancomycin In The Treatment Of Adult Methicillin Resistant Staphylococcus Aureus Bacteremia

BACKGROUND:Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is a fatal infectious disease, vancomycin is its standard antibiotic treatment. But with the wide range of applications vancomycin, MRSA has decreased its sensitivity, and have appeared in the agency and vancomycin-resistant Staphylococcus aureus, vancomycin therefore encourage people to optimize drug delivery has more research, while there are more and more efficacy and safety study of other effects of antibiotic treatment of MRSA bacteremia.Objective:So as to provide some references for the clinical treatment of MRSA bacteremia better by vancomycin review current research in the treatment of MRSA bacteremia.Methods:In "vancomycin or antibiotic, Staphylococcus aureus or methicillin-resistant Staphylococcus aureus, bacteremia or bloodstream infection"and other keyword search to find out the related research of vancomycin in the treatment of MRSA bacteraemia, at the same time with other drugs in the treatment of MRSA bacteraemia.Result and conclusion:there are a lot of vancomycin and other antibiotics in the treatment of MRSA bacteraemia literature, integrated these results suggest that vancomycin treatment is still the first choice for the treatment of MRSA bacteraemia drugs; There is no evidence that vancomycin MIC value drift and its change is associated with mortality; No literature supports vancomycin treatment can shorten period of treatment, but continuous infusion can reduce the incidence of kidney damage.